GC Biopharma

녹십자 · 006280

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$1.1B (₩1.5T)

Overview

GC Biopharma makes medicines including blood-derived therapies, vaccines, prescription drugs, and over-the-counter products for human health.

It supplies these products to general hospitals, clinics, pharmaceutical wholesalers, pharmacies, and the Red Cross. Listed on KOSPI, Korea's main stock exchange, the company's product portfolio is anchored by blood-derived therapies and vaccines, which lead its overall medicine lineup.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$1.4B

▲ +18.5% YoY

Operating profit · FY2025

US$50.1M

▲ +115.4% YoY

Net income · FY2025

−US$21.5M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$1.2B(₩1.6T)	US$1.2B(₩1.7T)	US$1.4B(₩2T)
Operating profit	US$25M(₩34.4B)	US$23.3M(₩32.1B)	US$50.1M(₩69.1B)
Net income	−US$14.4M(−₩19.8B)	−US$30.9M(−₩42.6B)	−US$21.5M(−₩29.7B)

Revenue

FY2023US$1.2B
FY2024US$1.2B
FY2025US$1.4B

Operating profit

FY2023US$25M
FY2024US$23.3M
FY2025US$50.1M

Net income

FY2023−US$14.4M
FY2024−US$30.9M
FY2025−US$21.5M

Key ratios (FY2025)

ROE

-2.1%

Debt/Eq

113.1%

Op. margin

3.5%

Net margin

-1.5%

Rev. YoY

▲ +18.5%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?